1,101 filings
6-K
AZN
Astrazeneca plc
30 Dec 19
Lynparzaapproved In the Us As a 1ST-LINE Maintenance Treatment of Germline Brca-mutated Metastatic Pancreatic Cancer
6:46am
6-K
AZN
Astrazeneca plc
23 Dec 19
Astrazeneca's Triple-combination Therapy Approved In China for Patients with Copd
8:04am
6-K
AZN
Astrazeneca plc
23 Dec 19
Enhertu (Trastuzumab Deruxtecan) Approved In the Us for HER2-POSITIVE Unresectable or Metastatic Breast Cancer Following Two or More Prior ANTI-HER2 Based Regimens
7:33am
6-K
AZN
Astrazeneca plc
20 Dec 19
Astrazeneca Divests Rights to Arimidex and Casodex In Europe and Certain Additional Countries
7:12am
6-K
AZN
Astrazeneca plc
17 Dec 19
Fda Panel Backs Lynparza Use for Pancreatic Cancer
1:56pm
6-K
53bdoemz
16 Dec 19
Seroquel Rights Agreement Complete: Europe, Russia
6:46am
6-K
ai1cszv3dssesn46
12 Dec 19
Imfinzi Approved In China for the Treatment of Unresectable, Stage III Non-small Cell Lung Cancer Based on the Phase III Pacific Trial
6:30am
6-K
543b87 ygz44f
11 Dec 19
Trastuzumab Deruxtecan Achieved a Tumour Response Rate of 60.9% In Pivotal Phase II HER2-POSITIVE Metastatic Breast Cancer Trial
9:45am
6-K
9zhxjxib3nqd 5m8
5 Dec 19
Lynparza Approved In China As a 1ST-LINE Maintenance Therapy In Brca-mutated Advanced Ovarian Cancer
6:14am
6-K
fr73a3pov03fqn z93
3 Dec 19
Astrazeneca Divests Rights to Seroquel and Seroquel XR In the Us and Canada
8:29am
6-K
7g1457mw2j4d51kigv
2 Dec 19
Block Listing Interim Review
2:40pm
6-K
bwxv7g2ptt3zrpip6jy
2 Dec 19
Total Voting Rights
2:22pm
6-K
ij6 tu1zj
29 Nov 19
Imfinzi Granted Fda Priority Review for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer
9:11am
6-K
omcjvil
21 Nov 19
Calquence Approved In the Us for Adult Patients with Chronic Lymphocytic Leukaemia
2:52pm
6-K
e9l3042jg
15 Nov 19
Qtrilmet Approved In the Eu for Treatment of T2D
7:30am
6-K
dsgizlc6
14 Nov 19
Fda Accepts Regulatory Submission for Selumetinib
8:15am
6-K
gzbd85awbidtrdxeg
12 Nov 19
Anifrolumab Demonstrated Superiority Across Multiple Efficacy Endpoints In Patients with Systemic Lupus Erythematosus In Phase III Tulip 2 Trial
6:50am
6-K
08ojogkh
12 Nov 19
Roxadustat Phase III Programme Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk In Patients with Anaemia from Chronic Kidney Disease
6:03am
6-K
m6mlaj
8 Nov 19
Roxadustat Significantly Increased Haemoglobin Levels for Chronic Kidney Disease Patients with Anaemia In Phase III Olympus and Rockies Trials
10:05am
F-3ASR
lbh6 h7518c
8 Nov 19
Automatic shelf registration (foreign)
8:56am